参见附件。
[4] Ponzone R，Biglia N，Jncomuzzi Me，et al.Antihormones in prevention and treatment of breast cancer. Ann NYAcad sci，2006，1089：143-158.
[5] Fisher B，Jeong JH，Bryant J，et al.Treatment of Lymphnode-negative，oestrogen-receptor-positive breast cancer：long-term findings from National Surgical Adjuvant Breast and Bowel project randomised clinical trials. Lancet，2004，364(9437)：858-868.
[6] Howell A，Cuzick J，BaumM，et al.Results of the ATAC(Arimidex，Tamoxifen，Alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet，2005，365(9453)：60-62.
[7] Coombes RC，Hall E，Gibson LJ，et al.A randomized trial of exemestane afnter two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med，2004，350(11)：1081-1092.
[8] JaKesz R，Jonat W，Gnant M，et al.Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen：combined results of ABCSG trial 8 and ARNO q5 trial. Lancet，2005，366(9484)：455-462.
[9] Goss PE，Ingle JN，Martino S，et al.A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med，2003，349(19)：1793-1802.
[10] Houssami N，Guzict J，Dixon JM.The prevention detection and management of breast cancer. Med J Aust，2006，184(5)：230-234.
